Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RAP1A
REST API REST API
Homo sapiens
RAP1A is differentially expressed in 291 experiments: 115 organism parts: heart, testis, ... (113 more);, 188 disease states: normal, acute myeloid leukemia, ... (186 more);, 102 cell types 400 cell lines 41 compound treatments and 75 other conditions.
Synonyms SMGP21, KREV-1
Orthologs RAP1A (2 of 2) (Danio rerio)   RAP1A (Gallus gallus)   Rap1a (Mus musculus)   RSR1 (Saccharomyces cerevisiae)   Rap1a (Rattus norvegicus)   RAP1A_BOVIN (Bos taurus)   rap1a (Danio rerio)   Rap2l (Drosophila melanogaster)   rap1b (Xenopus laevis)   rap1a (Xenopus laevis)   RAP1A (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, GTPase activity, protein binding, intracellular, membrane, intracellular protein transport, blood coagulation, GTP catabolic process, GTP binding, activation of MAPKK activity, small GTPase mediated signal transduction, nucleotide binding, nucleocytoplasmic transport, signal transduction, protein transport, energy reserve metabolic process, Ras GTPase binding, guanyl-nucleotide exchange factor complex, nerve growth factor receptor signaling pathway, regulation of insulin secretion
InterPro Term Ran_GTPase, MIRO-like, ProtSyn_GTP-bd, Small_GTPase, Small_GTP-bd_dom, Small_GTPase_ARF/SAR, Small_GTPase_Ras, Small_GTPase_Rho, Small_GTPase_Rab_type
UniProt Accession P62834, A8KAH9, F8WBC0
Search EB-eye ENSG00000116473
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
primary culture
2
E-GEOD-2450, E-GEOD-1657
HCC1143
2
E-MTAB-37, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
HepG2
1
2
E-GEOD-21154, E-MTAB-37, E-GEOD-7307
HL-60
1
2
E-MTAB-37, E-GEOD-5258, E-GEOD-24147
394 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (46 experiments)

Factor Value U/D Experiments
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
basal cell
1
E-GEOD-3998
activated natural killer cell
1
E-TABM-702
double positive thymocyte
1
E-GEOD-1460
induced pluripotent stem cell
1
E-GEOD-18147
adult native RPE from 76 y.o. donor
1
E-GEOD-18811
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, ... (60 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
prostate carcinoma
3
E-MEXP-2034, E-MTAB-37, E-TABM-26
squamous cell carcinoma
2
E-MTAB-37, E-MTAB-62
lung carcinoma
2
E-GEOD-6014, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
182 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-5824, ... (27 experiments)

Factor Value U/D Experiments
none
2
9
E-GEOD-5824, E-MEXP-1958, E-TABM-782, E-GEOD-412, E-GEOD-4668, ... (11 experiments)
ox-LDL
1
E-GEOD-5741
heregulin
1
E-GEOD-6462
rapamycin
1
E-GEOD-5824
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
hydrogen peroxide
1
E-GEOD-5339
35 more value(s).


Age years

studied in E-TABM-783

Factor Value U/D Experiments
n/a
1
1
E-TABM-783
1
1
E-TABM-783


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (9 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (10 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.344 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM